TY - JOUR AU - Fennell, D. A. AU - Rudd, R. M. PY - 2004 DA - 2004// TI - Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development JO - Lancet Oncol VL - 5 UR - https://doi.org/10.1016/S1470-2045(04)01492-5 DO - 10.1016/S1470-2045(04)01492-5 ID - Fennell2004 ER - TY - JOUR AU - Fennell, D. A. PY - 2008 DA - 2008// TI - Advances in the systemic therapy of malignant pleural mesothelioma JO - Nat Clin Pract Oncol VL - 5 UR - https://doi.org/10.1038/ncponc1039 DO - 10.1038/ncponc1039 ID - Fennell2008 ER - TY - JOUR AU - van Meerbeeck, J. P. PY - 2005 DA - 2005// TI - Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.20005.14.589 DO - 10.1200/JCO.20005.14.589 ID - van Meerbeeck2005 ER - TY - JOUR AU - Vogelzang, N. J. PY - 2003 DA - 2003// TI - Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.11.136 DO - 10.1200/JCO.2003.11.136 ID - Vogelzang2003 ER - TY - JOUR AU - Zalcman, G. PY - 2016 DA - 2016// TI - Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01238-6 DO - 10.1016/S0140-6736(15)01238-6 ID - Zalcman2016 ER - TY - JOUR AU - Herbst, R. S. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - STD TI - Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–508. ID - ref7 ER - TY - STD TI - Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. ID - ref8 ER - TY - JOUR AU - Mansfield, A. S. PY - 2014 DA - 2014// TI - B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000177 DO - 10.1097/JTO.0000000000000177 ID - Mansfield2014 ER - TY - JOUR AU - Khanna, S. PY - 2016 DA - 2016// TI - Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the Anti-PD-L1 antibody avelumab JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.07.033 DO - 10.1016/j.jtho.2016.07.033 ID - Khanna2016 ER - TY - JOUR AU - Tumeh, P. C. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Alley, E. W. PY - 2017 DA - 2017// TI - Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30169-9 DO - 10.1016/S1470-2045(17)30169-9 ID - Alley2017 ER - TY - JOUR AU - Hassan, R. PY - 2016 DA - 2016// TI - Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression JO - J Clin Oncol VL - 34 ID - Hassan2016 ER - TY - JOUR AU - Quispel-Janssen, J. PY - 2017 DA - 2017// TI - OA13.01 A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with Translational Research (TR) biopies JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.300 DO - 10.1016/j.jtho.2016.11.300 ID - Quispel-Janssen2017 ER - TY - JOUR AU - Krug, L. M. PY - 2015 DA - 2015// TI - Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70056-2 DO - 10.1016/S1470-2045(15)70056-2 ID - Krug2015 ER - TY - JOUR AU - Thapa, B. PY - 2017 DA - 2017// TI - The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.02.013 DO - 10.1016/j.jtho.2017.02.013 ID - Thapa2017 ER - TY - JOUR AU - Pocock, S. J. PY - 2006 DA - 2006// TI - Current controversies in data monitoring for clinical trials JO - Clin Trials VL - 3 UR - https://doi.org/10.1177/1740774506073467 DO - 10.1177/1740774506073467 ID - Pocock2006 ER - TY - JOUR AU - Freidlin, B. AU - Korn, E. L. AU - Gray, R. PY - 2010 DA - 2010// TI - A general inefficacy interim monitoring rule for randomized clinical trials JO - Clin Trials VL - 7 UR - https://doi.org/10.1177/1740774510369019 DO - 10.1177/1740774510369019 ID - Freidlin2010 ER -